Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Humain Ventures is a venture capital firm founded in 2023, with offices in Austin and New York. The firm specializes in the health sector, particularly focusing on the integration of biology and artificial intelligence. Humain Ventures aims to support early-stage companies that are innovating in therapeutics, biosensing, and preventive healthcare. The firm is committed to engineering better healthcare solutions through advanced technology.
As of now, Humain Ventures has launched its first fund, Humain Ventures Fund I, which is dedicated to investing in startups that leverage AI and biotechnology to create innovative healthcare solutions. The firm is actively building its portfolio and establishing itself as a key player in the TechBio space.
Humain Ventures invests primarily in the health industry, targeting companies at various stages of development, including pre-seed, seed, and Series A. The firm is particularly interested in startups that utilize artificial intelligence and biotechnology to enhance healthcare outcomes. Their investment strategy emphasizes the importance of innovation in therapeutics, biosensing, and preventive healthcare.
The firm seeks to partner with visionary entrepreneurs who are shaping the future of healthcare. Humain Ventures looks for companies that demonstrate a strong potential for growth and innovation, particularly those that can effectively integrate AI into their healthcare solutions. The firm’s thesis revolves around TechBio, focusing on how AI, computation, and biotechnology can improve drug discovery and healthcare delivery.
Humain Ventures has made a notable investment in the following company:
Aneil Mallavarapu - Managing Partner. Aneil has a background in TechBio and healthcare, having previously worked at Precise.ly, Fullbottle, and Takeda Oncology. He is also associated with Harvard Medical School, where he has contributed to research in the field.
Linea Avey - Managing Partner. Linea is a co-founder of 23andMe and has extensive experience in the TechBio sector. She is recognized for her pioneering work in integrating technology with biology and is a key figure at Humain Ventures.
To pitch Humain Ventures, founders should visit their website at humain.vc or send an email to contact@humain.vc. It is recommended to include a detailed pitch deck that outlines the business model, market analysis, and technology integration.
While specific response times are not disclosed, founders should expect a thorough review process. Warm introductions may enhance the chances of receiving a timely response, but direct pitches are also welcome.
In December 2023, Humain Ventures participated in the $32 million Series A funding round for Unnatural Products, a TechBio company focused on AI-enhanced chemistry for molecularly targeted therapeutics. This investment highlights the firm's commitment to supporting innovative healthcare solutions.
As of 2025, Humain Ventures continues to be active in the TechBio space, with Aneil Mallavarapu and Linea Avey recognized as leaders in the field. Their involvement in various industry events and discussions underscores the firm's dedication to advancing healthcare through technology.
What are Humain Ventures' investment criteria?
Humain Ventures focuses on early-stage investments in the health sector, particularly in companies that utilize AI and biotechnology. They target pre-seed, seed, and Series A stages, looking for startups that demonstrate innovative approaches to healthcare.
How can I pitch to Humain Ventures?
Founders can pitch their startups by visiting the Humain Ventures website at humain.vc or by emailing their pitch to contact@humain.vc. It is advisable to include a clear overview of the business model, market potential, and how the startup leverages AI or biotechnology.
What makes Humain Ventures different from other investors?
Humain Ventures distinguishes itself by focusing exclusively on the health sector and investing at the intersection of biology and AI. Their expertise in TechBio allows them to provide strategic guidance and industry connections to their portfolio companies.
What is the geographic focus of Humain Ventures?
The firm primarily invests in North America, specifically within the United States, targeting innovative health startups that are positioned to make significant impacts in the healthcare industry.
What is the typical check size for investments?
While specific check sizes have not been disclosed, Humain Ventures is known to participate in early-stage funding rounds, which typically range from hundreds of thousands to several million dollars, depending on the startup's needs and growth potential.
What kind of support do portfolio companies receive?
Humain Ventures adds value to its portfolio companies by leveraging its expertise in TechBio and healthcare. They provide strategic guidance, facilitate connections within the industry, and support growth and innovation initiatives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.